- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Piramal Pharma Limited — Updates, 29-01-2026: Press Release
29-01-2026 | 12:25 am
29-01-2026 | 12:25 am
Piramal Pharma's Q3/9M results were muted due to inventory destocking and slow early orders, impacting revenue to ₹2,140 Cr and EBITDA to ₹239 Cr. Outlook brightens with order inflow pick-up, US$90Mn capex on track, and the strategic Kenalog acquisition.
No comments yet. Be the first to comment!